LU502600B1 - Composition for reducing blood uric acids and preparation method and application thereof - Google Patents
Composition for reducing blood uric acids and preparation method and application thereof Download PDFInfo
- Publication number
- LU502600B1 LU502600B1 LU502600A LU502600A LU502600B1 LU 502600 B1 LU502600 B1 LU 502600B1 LU 502600 A LU502600 A LU 502600A LU 502600 A LU502600 A LU 502600A LU 502600 B1 LU502600 B1 LU 502600B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- composition
- preparation
- blood uric
- reducing blood
- calathide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 239000008280 blood Substances 0.000 title claims abstract description 36
- 210000004369 blood Anatomy 0.000 title claims abstract description 36
- 150000007968 uric acids Chemical class 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 150000007965 phenolic acids Chemical class 0.000 claims abstract description 20
- 235000009048 phenolic acids Nutrition 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 75
- 241000208818 Helianthus Species 0.000 claims description 35
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 32
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000011458 pharmacological treatment Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 23
- 238000002481 ethanol extraction Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 7
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 6
- 235000004883 caffeic acid Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 3
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 3
- 229940074360 caffeic acid Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 3
- 239000003640 drug residue Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present disclosure relates to a composition for reducing blood uric acids and a preparation method and application thereof, and particularly relates to the field of pharmacological treatment. The present disclosure provides a composition for reducing blood uric acids. Effective components of the composition consist of phenolic acids with a mass percentage of 37%. The composition of the present disclosure is capable of achieving the effect of reducing the level of blood uric acids, and meanwhile has small toxic or side effects.
Description
BL-5542
COMPOSITION FOR REDUCING BLOOD URIC ACIDS AND PREPARATION LU502600
METHOD AND APPLICATION THEREOF
[01] The present disclosure relates to the field of pharmacological treatment, in particular to a composition for reducing blood uric acids and a preparation method and application thereof.
[02] There are fewer studies or no large-scale studies on compounds of traditional Chinese medicine for the prevention and treatment of hyperuricemia (HUA), fewer compounds can be really and widely applied clinically, and almost no traditional Chinese medicine are available for treating gout on the current market. Thus, search of novel anti-HUA drugs with high efficiency and low toxicity is still a hot spot in current research.
[03] In order to solve the above problem, the present disclosure provides a composition for reducing blood uric acids and a preparation method and application thereof. The composition of the present disclosure is capable of achieving the effect of reducing the level of blood uric acids, and meanwhile has small toxic or side effects
[04] In order to achieve the above purpose, the present disclosure provides the following technical solution:
[05] The present disclosure provides a composition for reducing blood uric acids, and effective components of the composition are phenolic acids with a mass of 37% that of the composition.
[06] The present disclosure provides a preparation method of the above composition, including the following steps:
[07] soaking a sunflower calathide with seeds removed after mixing it with water, decocting it for 2 h, and filtering the mixtures with a 300-mesh filter sieve, to obtain filtrates; and
[08] enabling the concentrated filtrates to pass through macroporous resin columns, conducting elution with water and ethanol aqueous solutions with volume percentages of 10%, 20%, 60% and 70% respectively in sequence, collecting eluates of the ethanol aqueous solutions by sections, and obtaining the composition for reducing blood uric acids; wherein amounts of the water and the ethanol aqueous solutions with the volume percentages of 10%, 20%, 60% and 70% respectively are all 3 times of a volume of the macroporous resin columns.
[09] Preferably, the method further comprises cutting up the sunflower calathide before soaking, wherein a particle size of the chopped sunflower calathide is 3 cm.
[10] Preferably, the decoction and filtration are conducted for 2 times; and a mass of the water for each decoction is 20 times that of sunflower calathide blocks.
[11] Preferably, the concentration temperature is 80°C.
[12] Preferably, the method further includes centrifuging after concentration, wherein the rotating speed of centrifuging is 4000 rpm, and the time is 2 min. 1
BL-5542
[13] Preferably, the method further includes concentrating and drying the collected eluates in sequence after collecting the eluates of the ethanol solutions by sections. LU502600
[14] The present disclosure provides application of the above composition or the composition prepared by the above preparation method in preparation of a drug for reducing blood uric acids.
[15] The present disclosure provides a drug for reducing blood uric acids. The drug includes the above composition or the composition prepared by the above preparation method.
[16] Beneficial effects: the present disclosure provides the composition prepared from phenolic acids with the mass percentage of 37%, and the composition of the present disclosure is capable of reducing the level of blood uric acids, and has small toxic or side effects.
Experimental results showed that: by administrating the composition by gavage, the expression of URAT1 protein can be significantly reduced, and the level of blood uric acids of mice can be significantly lowered.
[17] The sunflower calathide is used as a raw material in the present disclosure for extraction so that waste of resources can be avoided.
[18] FIG. 1 is a standard curve of caffeic acids; and
[19] Unless otherwise specified, all materials used in the present disclosure can be conventionally purchased by those skilled in the art.
[20] The present disclosure provides a composition for reducing blood uric acids, and effective components of the composition are phenolic acids with a mass of 37% that of the composition. Inhibition of the composition of the present disclosure for URAT1 protein is superior to that of benzbromarone for the URAT1 protein, thereby achieving the effect of reducing blood uric acids, and the composition has small side effects.
[21] The present disclosure provides a preparation method of the above composition, including the following steps:
[22] soaking a sunflower calathide with seeds removed after mixing it with water, decocting it for 2 h, and filtering the mixtures with a 300-mesh filter sieve, to obtain filtrates; and
[23] the concentrated filtrates are enabled to pass through macroporous resin columns, elution is conducted with water and ethanol aqueous solutions with volume percentages of 10%, 20%, 60% and 70% respectively in sequence, eluates of the ethanol aqueous solutions are collected by sections, and the composition for reducing blood uric acids is obtained; wherein amounts of the water and the ethanol aqueous solutions with the volume percentages of 10%, 20%, 60% and 70% respectively are all 3 times of a volume of the macroporous resin columns.
[24] In the present disclosure, the sunflower calathide with seeds removed is mixed with water to be soaked, filtering is conducted after decocting for 2 h, and the filtrates are obtained.
A decocting manner is not limited in the present disclosure at all, and the manner known to those killed in the art is adopted.
[25] In the present disclosure, the method preferably further includes cutting up the 2
BL-5542 sunflower calathide before soaking; wherein a particle size of the chopped sunflower calathide is preferably 3 cm. LUS02600
[26] In the present disclosure, the soaking time is preferably 30 min; and the soaking temperature is preferably room temperature. In the present disclosure, the decoction and filtration are conducted for 2 times; and a mass of the water for each decoction is 20 times that of sunflower calathide blocks. A filtering manner is not limited in the present disclosure at all, and the manner known to those killed in the art is adopted.
[27] Inthe present disclosure, the concentrated filtrates pass through the macroporous resin columns, elution is conducted with the water and the ethanol aqueous solutions with volume percentages of 10%, 20%, 60% and 70% respectively in sequence, the eluates of the ethanol aqueous solutions are collected by sections, and the composition for reducing blood uric acids is obtained; wherein the amounts of the water and the ethanol aqueous solutions with the volume percentages of 10%, 20%, 60% and 70% respectively are all 3 times of the volume of the macroporous resin columns. In the present disclosure, a manner of passing through the macroporous resin columns is preferably a manner that supernatant obtained after centrifugation is slowly poured into the macroporous resin columns along walls of the macroporous resin columns. In the present disclosure, by slowly pouring the supernatant into the macroporous resin columns, macroporous resin can be effectively prevented from being rushed up, adsorption of the macroporous resin to the effective components is reduced, and then the effect of reducing blood uric acids by the composition prepared by the method of the present disclosure is ensured.
[28] In the present disclosure, the ethanol solutions at different concentrations are adopted for eluting, a manner of collecting the eluates by sections is beneficial to separating compounds with different polarities and adsorption capacities, and therefore it is ensured that the compounds needed by the present disclosure are obtained.
[29] In the present disclosure, the concentration temperature is preferably 80°C. In the present disclosure, the method preferably further includes centrifuging a concentrated solution obtained after concentration; wherein the rotating speed of centrifuging is preferably 4,000 rpm; and the centrifuging time is preferably 2 min.
[30] In the present disclosure, a model of the macroporous resin is preferably HPD500; the macroporous resin is preferably washed with 95% ethanol, water, IN HCI, water, IN NaOH, water and 95% ethanol in sequence; and the volume of the macroporous resin columns is preferably 120 ml. In the present disclosure, the 95% ethanol solution is preferably an ethanol solution with the volume percentage of 95%.
[31] In the present disclosure, the method preferably further includes concentrating and drying the eluates obtained by eluting ethanol solutions at different concentrations, to obtain the composition for reducing blood uric acids, namely a solid composition. In the present disclosure, the concentrating and drying temperature is preferably 80°C.
[32] In the present disclosure, the method further includes mixing the obtained dry composition after drying, to obtain the composition for reducing blood uric acids. A mixing manner is not limited in the present disclosure at all, and the manner known to those skilled in the art is adopted.
[33] The composition of the present disclosure can significantly reduce the expression of the URAT protein, and then ensures the effect of reducing blood uric acids, and therefore the composition can be used for preparing a drug for reducing blood uric acids. 3
BL-5542
[34] The present disclosure provides application of the above composition or the composition prepared by the above preparation method in preparation of a drug for reducing LU502600 blood uric acids.
[35] The present disclosure provides a drug for reducing blood uric acids, and the drug includes the above composition or the composition prepared by the above preparation method.
[36] In order to further describe the present disclosure, the composition for reducing blood uric acids and the preparation method and application thereof provided by the present disclosure are described in detail below with reference to drawings and embodiments, but they cannot be understood as limiting the protection scope the present disclosure.
Embodiment 1
[37] 1. Preparation of a composition for reducing blood uric acids
[38] (1) 100 g of sunflower calathide was cut into 3 cm pieces, and put into a 2 L round- bottom flask, water with a mass of 20 times that of the sunflower calathide was added for soaking for 30 min, then the round-bottom flask was heated for decocting the sunflower calathide for 2 h, and filtrates were collected by filtering; and water with a mass of 20 times that of the sunflower calathide continued to be added, drug residues were decocted for 2 h and filtered, and the filtrates were combined; and the filtrates were put into a water bath, and concentrated at 80°C to 700 mL for later use, 50 mL of concentrated solutions were taken, put into an evaporating dish, and evaporated to dryness, and a solid yield was calculated as 51.6%.
[39] (2) Macroporous resin with a model of HPD500 was washed with 95% ethanol, water,
IN HCI, water, IN NaOH, water and 95% ethanol in sequence, then the treated macroporous resin was packed into columns, a column packing volume was 120 mL, a loading liquid amount was 700 mL, and the concentrated solutions were poured into the columns along column walls slowly, and then eluted with water, a 10% ethanol solution, a 20% ethanol solution, a 60% ethanol solution and a 70% ethanol solution in sequence, wherein amounts of the water, the 10% ethanol solution, the 20% ethanol solution, the 60% ethanol solution and the 70% ethanol solution were all 3 times of the volume of the columns; and a water phase was removed, eluants were collected by sections, the ethanol eluants at different concentrations were respectively concentrated and dried in a water bath at 80°C into solids, to obtain compositions for reducing blood uric acids, and the solid compositions were mixed, to obtain the composition for reducing blood uric acids.
[40] 2. Determination of content of phenolic acids in composition
[41] (1) Preparation of caffeic acid reference solutions
[42] A proper amount of caffeic acid reference substances were taken and weighed precisely, and absolute methanol was added to prepare 90 ng/mL solutions, to obtain the caffeic acid reference solutions.
[43] (2) Preparation of a standard curve
[44] 025 mL, 0.5 mL, 1.0 mL, 1.5 mL, 2.0 mL and 2.5 mL of reference solutions were weighed accurately, and put into 25 mL volumetric flasks respectively, water was added into each volumetric flask to 6 mL, and 1 mL of 5% sodium nitrite solutions were added, shaken up, and placed for 6 min; 1 mL of 10% aluminum nitrate solutions were added, shaken up, and placed for 6 min; 10 mL of sodium hydroxide solutions were added, water was added again to the scale, the solutions were shaken up, and placed for 15 min, and the absorbance was 4
BL-5542 immediately determined at a S00 nm wavelength with an ultraviolet-visible spectrophotometry by taking corresponding reagents as blank; and the standard curve was drawn by taking the LU502600 absorbance as an ordinate and the concentration as an abscissa, results were shown in Table 1 and FIG. 2, the standard curve was: y=11.169x-0.2483, R2 was 0.9902, and the standard curve had a good linear relationship, and could be used for calculating the content of the phenolic acids.
Table 1 Absorbance results of phenolic acids with different concentrations
Content (mg) | 0025 | 0.045 | 0.09 | 0135 | 0.18 | 025
[45] (3) Preparation of a test solution
[46] 200 mg of the above composition solids for reducing blood uric acids were weighed accurately, a small amount of 70% ethanol solution was added for dissolving the composition solids, the solutions were transferred to a 50 mL volumetric flask, and 70% ethanol was added again to the scale, and shaken up, to obtain the test solution.
[47] (4) Determination method
[48] 0.5 mL of the above test solution was weighed accurately, and put into a 25 mL volumetric flask, absolute ethanol was added to 5 mL, 2.0 mL of 0.3% sodium lauryl sulphate and 1.0 mL of a mixed solution of 0.6% ferric chloride-0.9% potassium ferricyanide (1: 0.9) were added, shaken up, and placed in the dark for 5 min, and 0.1 mol/L of hydrochloric acid solution was added to the scale, shaken up, and placed in the dark for 20 min; and the absorbance was immediately determined at a 700 nm wavelength with the ultraviolet-visible spectrophotometry by taking corresponding reagents as blank, namely all reagents except for the test solution, the weight of caffeic acids in the test solution was read from the standard curve, and the content of the phenolic acids was obtained by calculation.
[49] The preparation process of the composition for reducing blood uric acids described above was repeated for 3 times, the composition for reducing blood uric acids extracted each time was determined, and experimental results were shown in Table 2.
Table 2 Determination result of content of phenolic acids in composition
Phenolic acids (mg) Solid content (mg)
[50] It could be known from experimental data recorded in Table 2 that by the adoption of the method provided by the present disclosure, the percentage of the phenolic acids was 36.8%- 37.4%, and it could be shown that the preparation method provided by the present disclosure was stable.
Comparative Example 1 [S51] 1.60% ethanol extraction process of sunflower calathide
[52] Preparation of a sunflower calathide ethanol extract: 100 g of sunflower calathide was cut into 3 cm pieces, and put into a 2 L round-bottom flask, a 60% ethanol solution with a mass of 10 times that of decoction pieces was added for soaking for 30 min, then the round-bottom
BL-5542 flask was heated for decocting the sunflower calathide for 1.5 h, filtrates were collected by filtering, a 60% ethanol solution with a mass of 10 times that of the sunflower calathide LU502600 continued to be added, drug residues were decocted for 1.5 h, and filtered, and the filtrates were combined, concentrated, and dried, to obtain a composition.
[53] 2. Determination of content of phenolic acids in composition
[54] Experimental operation was the same as the content measurement step 2 in
Embodiment 1.
[55] The 60% ethanol extraction process of the sunflower calathide described above was repeated for 3 times, the composition extracted each time was determined, and experimental results were shown in Table 3.
Table 3 Determination result of content of phenolic acids in composition extracted by 60% ethanol extraction process
[56] It could be shown from experimental data recorded in Table 3 that the percentage of the phenolic acids in the composition prepared by the method of the Comparative Example was 0.55%-0.56%.
Comparative Example 2
[57] 1. 80% ethanol extraction process of sunflower calathide
[58] Preparation of a sunflower calathide ethanol extract: 100 g of sunflower calathide was cut into 3 cm pieces, and put into a 2 L round-bottom flask, a 80% ethanol solution with a mass of 10 times that of the sunflower calathide was added for soaking for 30 min, then the round- bottom flask was heated for decocting the sunflower calathide for 1.5 h, filtrates were collected by filtering, a 80% ethanol solution with a mass of 10 times that of the sunflower calathide continued to be added, drug residues were decocted for 1.5 h, and filtered, and the filtrates were combined, concentrated, and dried, to obtain a composition.
[59] 2. Determination of content of phenolic acids in composition
[60] Experimental operation was the same as the content measurement step 2 in
Embodiment 1.
[61] The 80% ethanol extraction process of the sunflower calathide described above was repeated for 3 times, the composition extracted each time was determined, and experimental results were shown in Table 4.
Table 4 Determination result of content of phenolic acids in composition obtained by 80% ethanol extraction process 6
BL-5542
[62] It could be shown from experimental data recorded in Table 4 that the percentage of the phenolic acids in the composition prepared by the method of the Comparative Example was LU502600 1.06%-1.16%.
Comparative Example 3
[63] 1.80% ethanol extraction and water precipitation process of sunflower calathide
[64] (1) Preparation of a sunflower calathide 80% ethanol extract: experimental operation was the same as the operation step of item 1 in Comparative Example 2, and an extracting solution was obtained.
[65] (2) Preparation of a sunflower calathide ethanol extraction and water precipitation matter
[66] The above extracting solution was concentrated to a density of 1.1 g/mL, then water with a mass of 40 times of the volume was added, filtering was performed after standing for 12 h, and filtrates were dried, to obtain a composition.
[67] 2. Determination of the content in the composition
[68] Experimental operation was the same as the content measurement step 2 in
Embodiment 1.
[69] The 80% ethanol extraction and water precipitation process of the sunflower calathide described above was repeated for 3 times, the composition extracted each time was determined, and experimental results were shown in Table 5.
Table 5 Determination result of content of phenolic acids in composition obtained by ethanol extraction and water precipitation process
Tw awe
[70] It could be shown from experimental data recorded in Table 5 that the percentage of the phenolic acids in the composition prepared by the method of the Comparative Example was 9.0%-10.1%. 7
Claims (9)
1. A composition for reducing blood uric acids, characterized in that effective components of the composition are phenolic acids with a mass of 37% that of the composition.
2. A preparation method of the composition according to claim 1, characterized by comprising the following steps: soaking a sunflower calathide with seeds removed after mixing it with water, decocting it for 2 h, and filtering the mixtures with a 300-mesh filter sieve, to obtain filtrates; and enabling the concentrated filtrates to pass through macroporous resin columns, conducting elution with water and ethanol aqueous solutions with volume percentages of 10%, 20%, 60% and 70% respectively in sequence, collecting eluates of the ethanol aqueous solutions by sections, and obtaining the composition for reducing blood uric acids; wherein amounts of the water and the ethanol aqueous solutions with the volume percentage contents of 10%, 20%, 60% and 70% respectively are all 3 times of a volume of the macroporous resin columns.
3. The preparation method according to claim 2, characterized by further comprising: cutting up the sunflower calathide before soaking, wherein a particle size of the chopped sunflower calathide is 3 cm.
4. The preparation method according to claim 2, characterized in that the decoction and filtration are conducted for 2 times; and a mass of the water for each decoction is 20 times that of the sunflower calathide.
5. The preparation method according to claim 2, characterized in that the concentration temperature is 80°C.
6. The preparation method according to claim 2, characterized by further comprising: centrifuging after concentration, wherein the rotating speed of centrifuging is 4000 rpm, and the time is 2 min.
7. The preparation method according to claim 6, characterized by further comprising: concentrating and drying the collected eluates in sequence after collecting the eluates of the ethanol solutions by sections.
8. Application of the composition according to claim 1 or the composition prepared by the preparation method according to any one of claims 2-7 in preparation of a drug for reducing blood uric acids.
9. A drug for reducing blood uric acids, characterized in that the drug comprises the composition according to claim 1 or the composition prepared by the preparation method according to any one of claims 2-7 8
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU502600A LU502600B1 (en) | 2022-07-28 | 2022-07-28 | Composition for reducing blood uric acids and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU502600A LU502600B1 (en) | 2022-07-28 | 2022-07-28 | Composition for reducing blood uric acids and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU502600B1 true LU502600B1 (en) | 2024-02-01 |
Family
ID=89808346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU502600A LU502600B1 (en) | 2022-07-28 | 2022-07-28 | Composition for reducing blood uric acids and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| LU (1) | LU502600B1 (en) |
-
2022
- 2022-07-28 LU LU502600A patent/LU502600B1/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258588B (en) | Preparation method of peony general glycoside | |
| CN105294790A (en) | Method for extracting high-purity steviol glycosides from stevia rebaudiana | |
| CN111728984A (en) | Preparation method of degreased periplaneta americana extract | |
| CN101991633A (en) | Method for extracting tripterygium glycosides, and product and inclusion compound and medicinal composition thereof | |
| LU502600B1 (en) | Composition for reducing blood uric acids and preparation method and application thereof | |
| WO2022052394A1 (en) | Method for preparing delphinidin acylated anthocyanin | |
| CN104945532B (en) | The preparation method of Gynura divaricata polysaccharide | |
| CN101703669B (en) | Smilax china effective fractions and extraction as well as purification process thereof | |
| WO2014000119A1 (en) | Anti-tachyarrhythmia formulation and preparation method thereof | |
| Xiaoyong et al. | Retracted Article: Extraction of flavonoids and kinetics of purification by macroporous resins from quinoa | |
| CN106916065B (en) | Method for preparing high-purity chlorogenic acid from burdock roots | |
| CN113429442B (en) | Method for separating tectoridin and tectorigenin from water extraction residues of rhizoma et radix Sichuan blackberry lily | |
| CN108794551A (en) | A method of preparing high-purity gardenoside from gardenia yellow pigment waste liquor | |
| LU502598B1 (en) | Composition for preventing and treating hyperuricemia, and preparation method and application thereof | |
| CN106109668B (en) | Inhibit the purification process of liver cell lipid aggregation main effect phenols component in litchi pulp | |
| CN115300470A (en) | Prunella vulgaris tablet and preparation method thereof | |
| CN111588775B (en) | Belladonna extract and belladonna capsule compound preparation | |
| CN111150765B (en) | Fingered citron flavone extract and separation and purification method thereof | |
| CN101747402B (en) | Method for enriching and purifying malol in sedum kamtschaticum | |
| CN113662974A (en) | Preparation and purification method of water chestnut shell polyphenol extract | |
| CN107050095B (en) | Preparation method of gypenoside side chain oligosaccharide | |
| CN104496760B (en) | A kind of preparation method of high purity tyrosol | |
| CN103316197A (en) | Preparation method of allium chinensis saponins extract removing nitrite | |
| CN114990177B (en) | Preparation method of high-purity epimedium flavone low-glycoside component | |
| CN107927283B (en) | Method for extracting tea soup aroma substances by SPE (solid phase extraction) small column |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Effective date: 20240201 |